Benitec Wins Chinese Patent on Expressed RNAi HCV Therapy
October 11, 2012
Benitec Wins Chinese Patent on Expressed RNAi HCV Therapy
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UC, San Diego Selected as Site for Benitec HCV Drug Trial
April 18, 2013 / Gene Silencing News - Benitec Looks to Outlicense IP While Avoiding Litigation Mistakes of Its Past
November 8, 2012 / Gene Silencing News - Benitec Provides Pipeline Update Following Tacere Acquisition
October 18, 2012 / Gene Silencing News - Benitec Reacquires HCV Program in Tacere Therapeutics Buyout
October 11, 2012 / Gene Silencing News - Genable Receives FDA Orphan Drug Status for Ocular Disease Drug
April 18, 2013 / Gene Silencing News